Adial Pharmaceuticals to Present at The MicroCap Conference on October 1st in New York City
CHARLOTTESVILLE, VA / ACCESSWIRE / September 26, 2018 / Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; NASDAQ: ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today announced that William Stilley, President and Chief Executive Officer, will be presenting at this year's MicroCap Conference on Monday, October 1st at 9:30 AM, ET, at the Essex House in New York City. Management will also be available for one-on-one meetings with investors. Interested parties can contact Crescendo Communications at (212) 671-1021 or by email at firstname.lastname@example.org.
REGISTRATION FOR INVESTORS
To request free registration, please go to the MicroCap website (www.microcapconf.com), and click the "Registration" button
FOR MORE INFORMATION
Please visit: www.microcapconf.com
Or, contact Ashley Allard at email@example.com
News Compliments of ACCESSWIRE.
About Adial Pharmaceuticals, Inc.
Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of treatments for addictions. The Company's lead investigational new drug candidate, AD04, is a genetically targeted therapeutic agent for the treatment of alcohol use disorder (AUD). A Phase 2b clinical trial of AD04 for the treatment of AUD showed promising results in reducing frequency of drinking, quantity of drinking and heavy drinking (all with statistical significance), and no overt safety concerns (there were no statistically significant serious adverse events reported). The Company plans to commence a Phase 3 clinical trial using AD04 for the potential treatment of AUD in subjects with certain target genotypes, which are to be identified using the Company's proprietary companion diagnostic genetic test. AD04 is also believed to have the potential to treat other addictive disorders such as opioid use disorder, gambling, and obesity.
Crescendo Communications, LLC
David Waldman / Natalya Rudman
SOURCE: Adial Pharmaceuticals, Inc.
Released September 26, 2018